Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.

Research output: Contribution to journalLiterature review

13 Citations (Scopus)

Abstract

Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype.

Areas covered: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma.

Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward.
Original languageEnglish
Pages (from-to)143-149
Number of pages7
JournalExpert Review of Clinical Immunology
Volume13
Issue number2
Early online date2 Aug 2016
DOIs
Publication statusPublished - 2016

Fingerprint

Interleukin-13
Interleukin-5
Biological Products
Interleukin-4
Asthma
Biological Therapy
Phenotype
Biomarkers
Cytokines
Therapeutics
Eosinophilia
PubMed
Glucocorticoids
Language
Monoclonal Antibodies
Population

Keywords

  • asthma
  • IL-4
  • IL-5
  • IL-13
  • biologics
  • eosinophil

Cite this

Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update. / Walsh, Garry M.

In: Expert Review of Clinical Immunology , Vol. 13, No. 2, 2016, p. 143-149.

Research output: Contribution to journalLiterature review

@article{b2554c1ab98342859eae6a5ee4360d8b,
title = "Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.",
abstract = "Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype.Areas covered: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma.Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward.",
keywords = "asthma, IL-4, IL-5, IL-13, biologics, eosinophil",
author = "Walsh, {Garry M.}",
year = "2016",
doi = "10.1080/1744666X.2016.1216316",
language = "English",
volume = "13",
pages = "143--149",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.

AU - Walsh, Garry M.

PY - 2016

Y1 - 2016

N2 - Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype.Areas covered: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma.Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward.

AB - Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype.Areas covered: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma.Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward.

KW - asthma

KW - IL-4

KW - IL-5

KW - IL-13

KW - biologics

KW - eosinophil

U2 - 10.1080/1744666X.2016.1216316

DO - 10.1080/1744666X.2016.1216316

M3 - Literature review

VL - 13

SP - 143

EP - 149

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 2

ER -